What is Spatial Genomics?
Spatial Genomics is at the forefront of empowering scientific discovery through its advanced spatial analysis technology. The company's platform enables the simultaneous assaying of single-cell gene expression, protein expression, and genomic/epigenomic states within intact cells and tissues. This comprehensive approach allows researchers to catalog not just individual cell states but also their neighborhoods, interactions, and influences. Spatial Genomics' technology is poised to make substantial advancements in fundamental biology, precision medicine, drug development, and diagnostics, truly revealing deeper biological insights.
How much funding has Spatial Genomics raised?
Spatial Genomics has raised a total of $56M across 1 funding round:
Series A
$56M
Series A (2022): $56M with participation from Fulgent and 12 West Capital Management
Key Investors in Spatial Genomics
Fulgent
Fulgent is a premier, full-service genomic testing company founded in 2011, specializing in transforming patient care across oncology, rare diseases, and reproductive health. They are also developing drug candidates for cancer treatment, aiming to become a fully integrated precision medicine company.
12 West Capital Management
12 West Capital Management is an investment firm that has participated in Spatial Genomics' recent funding round, indicating a strategic interest in the company's advancements in spatial biology and its potential impact on precision medicine and drug development.
What's next for Spatial Genomics?
With the recent infusion of major strategic capital, Spatial Genomics is well-positioned to scale its operations and further develop its cutting-edge spatial analysis platform. The company's focus on precision medicine and drug development suggests a trajectory towards deeper integration with pharmaceutical and diagnostic sectors. Future growth will likely involve expanding its market reach, forging new partnerships, and continuing to innovate in the rapidly evolving field of multi-omic spatial biology. This substantial backing signals strong investor confidence in Spatial Genomics' vision to revolutionize biological understanding.
See full Spatial Genomics company page
